1. Home
  2. INVZ vs ENGN Comparison

INVZ vs ENGN Comparison

Compare INVZ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innoviz Technologies Ltd. Ordinary shares

INVZ

Innoviz Technologies Ltd. Ordinary shares

HOLD

Current Price

$0.64

Market Cap

144.1M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.88

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INVZ
ENGN
Founded
2016
1999
Country
Israel
Canada
Employees
415
82
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
144.1M
117.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
INVZ
ENGN
Price
$0.64
$1.88
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$2.68
$21.08
AVG Volume (30 Days)
3.3M
1.2M
Earning Date
05-14-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.61
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.40
52 Week High
$2.54
$12.25

Technical Indicators

Market Signals
Indicator
INVZ
ENGN
Relative Strength Index (RSI) 45.69 43.73
Support Level $0.59 $1.68
Resistance Level $0.74 $7.92
Average True Range (ATR) 0.06 0.09
MACD 0.01 0.10
Stochastic Oscillator 36.50 73.21

Price Performance

Historical Comparison
INVZ
ENGN

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: